Key result
Among patients with non-valvular atrial fibrillation, 31% were over-treated, and the presence of contraindications for oral anticoagulation strongly increased the risk of over-treatment (OR 37.0).
Cross-Sectional (n=981)
Yes
Odds Ratio: 37 (95% CI 18.1–79.9)
p-value: p=<0.01
In general practice, antithrombotic treatment for non-valvular atrial fibrillation frequently deviates from guidelines, with significant under-treatment in patients with previous stroke and over-treatment in those with contraindications.
Over-treatment of NVAF patients with contraindications signals guideline discordance in practice; leaves open drivers of real-world deviations for prospective study.
OBJECTIVE: To determine adequacy of antithrombotic treatment in patients with non-valvular atrial fibrillation. To determine risk factors for under- and over-treatment. DESIGN: Retrospective, cross-sectional study of electronic health records from 36 general practitioners in 2008. SETTING: General practice in the Netherlands. SUBJECTS: Primary care physicians (n = 36) and patients (n = 981) aged 65 years and over. MAIN OUTCOME MEASURES: Rates of adequate, under and over-treatment, risk factors for under and over-treatment. RESULTS: Of the 981 included patients with a mean of age 78, 18% received no antithrombotic treatment (under-treatment), 13% received antiplatelet drugs and 69% received oral anticoagulation (OAC). Further, 43% of the included patients were treated adequately, 26% were under-treated, and 31% were over-treated. Patients with a previous ischaemic stroke were at high risk for under-treatment (OR 2.4, CI 1.6-3.5), whereas those with contraindications for OAC were at high risk for over-treatment (OR 37.0, CI 18.1-79.9). Age over 75 (OR 0.2, CI: 0.1-0.3]), diabetes (OR 0.1, CI: 0.1-0.3), heart failure (OR 0.2, CI: 0.1-0.3), hypertension (OR 0.1, CI: 0.1-0.2) and previous ischaemic stroke (OR 0.04, CI: 0.02-0.11) protected against over-treatment. CONCLUSIONS: In general practice, CHADS2-criteria are being used, but the antithrombotic treatment of patients with atrial fibrillation frequently deviates from guidelines on this topic. Patients with previous stroke are at high risk of not being prescribed OAC. Contraindications for OAC, however, seem to be frequently overlooked.
No takes yet. Share an insight, caveat, or question.
Arts et al. (2013) conducted a cross-sectional in Non-valvular atrial fibrillation (n=981). Contraindications for oral anticoagulation vs. No contraindications for oral anticoagulation was evaluated on Over-treatment with antithrombotic therapy (OR 37.0, 95% CI 18.1-79.9, p=<0.01). Among patients with non-valvular atrial fibrillation, 31% were over-treated, and the presence of contraindications for oral anticoagulation strongly increased the risk of over-treatment (OR 37.0).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: